The Institute for International Research will be holding their 13th Annual Business of Biosimilars and Generic Drugs event in Boston on September 10-12, 2012 at the Hilton Boston Back Bay.
This is the only conference in the United States devoted entirely to building and executing a reliable market-entry and commercialization strategy for your follow-on biopharmaceuticals.
The expert faculty will provide you with senior executive-level expert insight on all of your critical success factors:
* An up-to-date toolkit for regulatory submission packages that will guarantee timely approval, including the latest insights on the FDA’s draft guidelines for biosimilars
* Success strategies from industry leaders on how to overcome IP challenges and guarantee product availability
* An unequaled spectrum of international case studies offering lessons on the commercialization of biosimilars and generic drugs in North and South America, Western and Eastern Europe, North Africa, the Middle East, and the Far East
And in an unprecedented step that will help provide a clear path towards reimbursement of the newer product class, this year we have multiple discussions aimed at specifically translating into a biosimilars context the market success strategies employed by generic drugs.
For more information please visit www.biosimilarsevent.com